|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Viola D, Valerio L, Molinaro E, Agate L,
Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C,
et al: Treatment of advanced thyroid cancer with targeted
therapies: Ten years of experience. Endocr Relat Cancer.
23:R185–R205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel UJ and May M: Lenvatinib in the
treatment of differentiated thyroid cancer and advanced renal cell
carcinoma. J Adv Pract Oncol. 8:757–64. 2017.PubMed/NCBI
|
|
4
|
Oyer SL, Fritsch VA and Lentsch EJ:
Comparison of survival rates between papillary and follicular
thyroid carcinomas among 36,725 patients. Ann Otol Rhinol Laryngol.
123:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toniato A, Boschin I, Casara D, Mazzarotto
R, Rubello D and Pelizzo M: Papillary thyroid carcinoma: Factors
influencing recurrence and survival. Ann Surg Oncol. 15:1518–1522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carbone C, Piro G, Merz V, Simionato F,
Santoro R, Zecchetto C, Tortora G and Melisi D: Angiopoietin-like
proteins in angiogenesis, inflammation and cancer. Int J Mol Sci.
19:4312018. View Article : Google Scholar
|
|
7
|
Cinkajzlová A, Mráz M, Lacinová Z,
Kloučková J, Kaválková P, Kratochvílová H, Trachta P, Křížová J,
Haluzíková D, Škrha J, et al: Angiopoietin-like protein 3 and 4 in
obesity, type 2 diabetes mellitus, and malnutrition: The effect of
weight reduction and realimentation. Nutr Diabetes. 8:212018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geladari E, Tsamadia P and Vallianou NG:
ANGPTL3 inhibitors-their role in cardiovascular disease through
regulation of lipid metabolism. Circ J. 83:267–273. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hato T, Tabata M and Oike Y: The role of
angiopoietin-like proteins in angiogenesis and metabolism. Trends
Cardiovasc Med. 18:6–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang CC, Kaba M, Ge G, Xie K, Tong W, Hug
C and Lodish HF: Angiopoietin-like proteins stimulate ex vivo
expansion of hematopoietic stem cells. Nat Med. 12:240–245. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC,
Pal M, Lam CR, Boukamp P, Pan JY, Tan SH, et al: Angiopoietin-like
4 protein elevates the prosurvival intracellular
O2(−):H2O2 ratio and confers
anoikis resistance to tumors. Cancer Cell. 19:401–415. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tabata M, Kadomatsu T, Fukuhara S, Miyata
K, Ito Y, Endo M, Urano T, Zhu HJ, Tsukano H, Tazume H, et al:
Angiopoietin-like protein 2 promotes chronic adipose tissue
inflammation and obesity-related systemic insulin resistance. Cell
Metab. 10:178–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim I, Kwak HJ, Ahn JE, So JN, Liu M, Koh
KN and Koh GY: Molecular cloning and characterization of a novel
angiopoietin family protein, angiopoietin-3. FEBS Lett.
443:353–356. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dhanabal M, Jeffers M, LaRochelle WJ and
Lichenstein HS: Angioarrestin: A unique angiopoietin-related
protein with anti-angiogenic properties. Biochem Biophys Res
Commun. 333:308–315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dhanabal M, LaRochelle WJ, Jeffers M,
Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog
FL, Padigaru M, et al: Angioarrestin: An antiangiogenic protein
with tumor-inhibiting properties. Cancer Res. 62:3834–3841.
2002.PubMed/NCBI
|
|
16
|
Smagur A, Szary J and Szala S: Recombinant
angioarrestin secreted from mouse melanoma cells inhibits growth of
primary tumours. Acta Biochim Pol. 52:875–879. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ,
Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, et al: Angiopoietin-like
protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin
Invest. 127:4202017. View
Article : Google Scholar
|
|
18
|
Sasaki H, Moriyama S, Sekimura A, Mizuno
K, Yukiue H, Konishi A, Yano M, Kaji M, Fukai I, Yamakawa Y and
Fujii Y: Angioarrestin mRNA expression in early-stage lung cancers.
Eur J Surg Oncol. 29:649–653. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen H, Xiao Q, Hu Y, Chen L, Jiang K,
Tang Y, Tan Y, Hu W, Wang Z, He J, et al: ANGPTL1 attenuates
colorectal cancer metastasis by up-regulating microRNA-138. J Exp
Clin Cancer Res. 36:782017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan Q, Jiang L, Liu M, Yu D, Zhang Y, Li
Y, Fang S, Li Y, Zhu YH, Yuan YF and Guan XY: ANGPTL1 Interacts
with Integrin alpha1beta1 to Suppress HCC Angiogenesis and
Metastasis by Inhibiting JAK2/STAT3 Signaling. Cancer Res.
77:5831–5845. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang C, Bo C, Guo L, Yu P, Miao S and Gu
X: BCL2 and hsa-miR-181a-5p are potential biomarkers associated
with papillary thyroid cancer based on bioinformatics analysis.
World J Surg Oncol. 17:2212019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Gao S, Jin Y, Yang Y, Tai J, Wang
S, ang H, Chu P, Han S and Lu J: Bioinformatics analysis to screen
key genes in papillary thyroid carcinoma. Oncol Lett. 19:195–204.
2020.PubMed/NCBI
|
|
23
|
Tuttle RM, Haugen B and Perrier ND:
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis
staging system for differentiated and anaplastic thyroid cancer
(Eighth Edition): What changed and Why? Thyroid. 27:751–756. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Adam MA, Thomas S, Roman SA, Hyslop T and
Sosa JA: Rethinking the Current American Joint Committee on Cancer
TNM staging system for medullary thyroid cancer. JAMA Surg.
152:869–876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang Z, Cai C, Han D, Gao Y, Li Q, Feng
L, Zhang W, Zheng J, Jin J, Zhang H and Wei Q: Anoctamin5 regulates
cell migration and invasion in thyroid cancer. Int J Oncol.
51:1311–1319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shang H, Wang S, Yao J, Guo C, Dong J and
Liao L: Salidroside inhibits migration and invasion of poorly
differentiated thyroid cancer cells. Thorac Cancer. 10:1469–1478.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen DL, Hu ZQ, Zheng XF, Wang XY, Xu YZ,
Li WQ, Fang HS, Kan L and Wang SY: EDAG-1 promotes proliferation
and invasion of human thyroid cancer cells by activating MAPK/Erk
and AKT signal pathways. Cancer Biol Ther. 17:414–421. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yarchoan M, Ma C, Troxel AB, Stopenski SJ,
Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA III, Chen EY,
Feldman MD and Brose MS: pAKT expression and response to sorafenib
in differentiated thyroid cancer. Horm Cancer. 7:188–195. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F and Schlumberger M: Long-term outcome of 444 patients
with distant metastases from papillary and follicular thyroid
carcinoma: Benefits and limits of radioiodine therapy. J Clin
Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Liu Y, Lin Y and Liang J:
Radioactive Iodine-refractory differentiated thyroid cancer and
redifferentiation therapy. Endocrinol Metab (Seoul). 34:215–225.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang RH, Wang S, Zhang H, Lan JJ, Xu GB,
Zhao YL, Wang L, Li YJ, Wang YL, Zhou YH, et al: Discovery of
tetrandrine derivatives as tumor migration, invasion and
angiogenesis inhibitors. Bioorg Chem. 101:1040252020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST,
Yen CJ, Yang CY, Sung SY and Su JL: Angiopoietin-like protein 1
antagonizes MET receptor activity to repress sorafenib resistance
and cancer stemness in hepatocellular carcinoma. Hepatology.
64:1637–1651. 2016. View Article : Google Scholar : PubMed/NCBI
|
